Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

Published:2023-07-04 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Hengeveld P. J.^ORCID,Schilperoord-Vermeulen J.,van der Klift M. Y.,Dubois J. M. N.,Kolijn P. M.,Kavelaars F. G.,Rijken M.,Dobber J. A.,Nasserinejad K.,Kersting S.,Westerweel P. E.^ORCID,Kater A. P.^ORCID,Langerak A. W.^ORCID,Levin M-D.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00870-2.pdf

Reference10 articles.

1. Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019;9:1–15.

2. Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, et al. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood. 2019;133:494–7.

3. Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049–60.

4. Seymour JF, Kipps TJ, Eichhorst BF, D’Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140:839–50.

5. Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers A-MF, et al. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematol. 2022;9:e190–9.